The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Odonate Therapeutics, Inc. (NASDAQ: ODT) who purchased shares between December 7, 2017 and April 21, 2020. The action, which was filed in the United States District Court for the Southern District of California, alleges that the Company violated federal securities laws.
In particular, the Odonate lawsuit alleges that (i) the Company’s orally administered chemotherapy agent, tesetaxel, was not as safe or well-tolerated as the Company had led investors to believe; (ii) consequently, tesetaxel’s commercial viability as a cancer treatment was overstated; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Shareholders have until November 16, 2020 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
To learn more and keep informed, complete this form >